IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today the publication of favorable
clinical results for the Nellix technology for the endovascular
repair of abdominal aortic aneurysm (EVAR). The peer-reviewed
article reported initial results from the international multicenter
clinical trial, with successful aneurysm exclusion in all patients,
and no late aneurysm or device-related adverse events or secondary
procedures.
Lead author and scientific advisor Carlos E. Donayre, MD (Harbor-UCLA Medical
Center, Torrance, CA) commented,
"The Nellix technology was designed to address the limitations of
currently available EVAR devices and to expand the therapy to more
patients. By filling the aneurysm sac, the Nellix device may
reduce the incidence of endoleaks, secondary interventions and the
need for annual CT scan follow-up. We are encouraged by these
promising results, and look forward to the availability of broader
experience in the near future."
The publication, entitled "Initial clinical experience with a
sac anchoring endoprosthesis for aortic aneurysm repair," was
published in the February issue of the Journal of Vascular Surgery
(JVS). The study examined the initial and one year outcomes
of 21 patients treated at four international centers. An
independent core laboratory analyzed preoperative and
post-procedural computed tomography scans to determine aneurysm
exclusion and device stability over time.
John McDermott, President and
Chief Executive Officer said, "We believe the Nellix technology
represents the next generation in endovascular repair of abdominal
aortic aneurysms. Since completing the acquisition in
December 2010, we are delighted that
initial results of the international trial are now published by a
peer review journal and we look forward to providing the clinical
community with updates as more data is available. In addition to
Nellix, our Ventana™ fenestrated stent graft and AFX system
continue to advance on schedule. We believe this robust new
product pipeline will enable us to expand the EVAR market and
continue to capture market share."
About Journal of Vascular Surgery
Journal of Vascular Surgery provides vascular, cardiothoracic,
and general surgeons with the most recent information in vascular
surgery. Original, peer-reviewed articles cover clinical and
experimental studies, noninvasive diagnostic techniques, processes
and vascular substitutes, microvascular surgical techniques,
angiography, and endovascular management. Special issues
publish papers presented at the annual meeting of the Society for
Vascular Surgery. Journal of Vascular Surgery ranks 14th of
166 journals in Surgery and 14th of 60 journals in the Peripheral
Vascular Disease categories on the 2009 Journal Citation Reports®,
published by Thomson Reuters, and has an Impact Factor of
3.517.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship
product is the Powerlink® System, which is an endovascular stent
graft for the treatment of abdominal aortic aneurysms (AAA).
AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement.
Once AAA develops, it continues to enlarge and, if left
untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site
at www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the success of sales efforts for the Powerlink System and related
new products, product research and development efforts, and other
economic, business, competitive and regulatory factors. The Company
undertakes no obligation to update its forward looking statements.
Please refer to the Company's Annual Report on Form 10-K for the
year ended December 31, 2009, and the
Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied.
|
|
|
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
SOURCE Endologix, Inc.